ArticleThe American journal of clinical nutrition2025
Relationship between skeletal muscle indicators and clinical outcomes in cystic fibrosis is modified by adiposity and CFTR modulator use: a cross-sectional analysis.
Article in The American journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMuscle mass predicts clinical outcomes in people with cystic fibrosis (PwCF), but muscle quality remains insufficiently characterized. Furthermore, although CFTR modulators promote weight gain, their impact on the relationship between muscle and clinical outcomes is unknown.
objectivesTo quantify the relationships between skeletal muscle indicators and clinical outcomes in adults with cystic fibrosis (CF) and determine whether CFTR modulators and/or adiposity influence the relationships.
methodsThis cross-sectional study included 75 adults with CF and 73 controls without CF. Body composition [appendicular skeletal muscle mass index (ASMI), visceral fat, and total body fat] was measured by dual-energy X-ray absorptiometry. Muscle quality (via phase angle) was assessed using bioelectrical impedance analysis. Clinical outcomes included physical functionality [hand grip (HG) strength and 1-min sit-to-stand test result], lung function, and an oral glucose tolerance test result. Sarcopenia was defined as having low muscle mass and low HG strength. Statistical analyses included testing for effect modification in the relationships between variables.
resultsFive PwCF had sarcopenia compared with none of the controls. Despite similar BMI, PwCF had lower ASMI [β: -0.46; 95% confidence interval (CI): -0.88, -0.05; P = 0.02], HG strength (β: -3.6; 95% CI: -6.6, -0.61; P = 0.02), and muscle quality (β: -0.57; 95% CI: -0.93, -0.21; P = 0.01) compared with controls. In PwCF, lung function was positively associated with ASMI among people not taking CFTR modulators but not among users (interaction; β: -9.21; 95% CI: -16.87, -1.55; P = 0.01). Muscle quality (r = 0.35; 95% CI: 0.04, 0.59; P = 0.02) and HG strength (r = 0.36; 95% CI: 0.05, 0.60; P = 0.02) were positively related to insulin sensitivity. The positive relationship between ASMI and physical functionality was only significant among PwCF with low adiposity (interaction; β: -1.9; 95% CI: -3.51, -0.35; P = 0.02).
conclusionsMuscle mass, strength, and quality are lower in PwCF than in controls, with muscle strength and quality linked to glucose tolerance. Lung function relationships with muscle mass differ by CFTR modulator use, and excess adiposity attenuates strength-related functional benefits. This study highlights the need for personalized approaches to CF management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.